Research into Bosutinib
Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Long-term Bosutinib For Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib Plus Dasatinib and/or Nilotinib
Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Bosutinib for the treatment of Philadelphia chromosome-positive leukemias.
Bosutinib for the treatment of chronic myeloid leukemia.
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
Tyrosine Kinase Inhibitor Induced Isolated Pericardial Effusion.
Bosutinib in Combination With the Aromatase Inhibitor Exemestane.
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia.
FDA accepts Pfizer leukemia treatment for review
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Global target profile
of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- Research from Austria
Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects
Bosutinib in the management of chronic myelogenous leukemia.
Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Phase II Results Show Bosutinib Safe, Effective for CML - Press release
from MD Anderson
therapy in chronic myeloid leukemia. - MD Anderson overview
chemical proteomics reveals mechanisms of action of clinical ABL kinase
inhibitors - abstract from Nature
(SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results
from a phase 1 study in patients with advanced malignant solid tumors.
- abstract from American Society of Clinical Oncology annual meeting in
2007. Concluded that bosutinib was well tolerated.